ACRP blog

OCTOBER 10, 2024

The increased accessibility of generative artificial intelligence (Gen AI) models like OpenAI’s ChatGPT and DALL-E has captured the popular imagination. You’d be hard-pressed now to find any leadership team in any sector that isn’t at least considering ways to leverage Gen AI. The technology uses patterns learned from data to create new content. Most industries have applied it to routine back office or administrative tasks, such as note-taking, helping to increase the efficiency of everyday pr

Clinical Trials 69

Clinical Trials Clinical Trials Trials Life Science 69

Bio Pharma Dive

OCTOBER 10, 2024

In a letter to Pfizer’s board, the activist investor claimed former CEO Ian Read and CFO Frank D’Amelio were pressured to abandon a Starboard-led attempt to change the company’s direction.

311

311

Pharmaceutical Technology

OCTOBER 10, 2024

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, US.

182

182

Bio Pharma Dive

OCTOBER 10, 2024

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Trials 279

Trials Marketing 279

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharmaceutical Technology

OCTOBER 10, 2024

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.

Development 147

Development Drugs 147

Bio Pharma Dive

OCTOBER 10, 2024

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

Gene Therapy 189

Gene Therapy Doctor Doctors Gene 189

Bio Pharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Drugs 173

Drugs Development 173

Pharmaceutical Technology

OCTOBER 10, 2024

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.

Allergies 130

Allergies 130

Bio Pharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Drugs 162

Drugs Development 162

Pharmaceutical Technology

OCTOBER 10, 2024

Biogen plans to start a Phase III trial for felzartamab as a treatment for antibody-mediated rejection, and two other indications in 2025.

Antibody 130

Antibody Trials 130

Advertisement

Clinical Supply

Bio Pharma Dive

OCTOBER 10, 2024

Attorneys argue Khan and two other commissioners are biased against pharmacy benefit managers and should recuse themselves from an ongoing lawsuit against the middlemen.

Pharmacy 130

Pharmacy 130

Pharmaceutical Technology

OCTOBER 10, 2024

As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are essential.

130

130

Pharma Times

OCTOBER 10, 2024

Teclistamab offers hope for patients exhausting treatment options

Drugs 127

Drugs 127

Pharmaceutical Technology

OCTOBER 10, 2024

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and Skysona.

Gene Therapy 130

Gene Therapy Gene Trials 130

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Bio Pharma Dive

OCTOBER 10, 2024

The FDA has authorized nearly 1,000 medical devices with artificial intelligence features as companies including GE Healthcare and Siemens Healthineers build out their AI efforts.

124

124

Pharmaceutical Technology

OCTOBER 10, 2024

At CPHI Europe, an expert discussed the promise of gummies as a drug delivery system and their unique manufacturing challenges.

Drug Delivery Systems 130

Drug Delivery Systems Drug Delivery Compliance Drugs 130

Fierce Pharma

OCTOBER 10, 2024

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. | As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio.

FDA Approval 124

FDA Approval Drugs 124

Pharmaceutical Technology

OCTOBER 10, 2024

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer treatment.

Development 130

Development 130

Advertisement

Clinical Supply

Pharma Times

OCTOBER 10, 2024

Sheffield cardiologists demonstrate cutting-edge TAVI procedure

124

124

Pharmaceutical Technology

OCTOBER 10, 2024

Arda Therapeutics has secured $43m in Series A financing led by Andreessen Horowitz to develop targeted cell depletion therapies.

Development 130

Development 130

Fierce Pharma

OCTOBER 10, 2024

Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting zbecker Thu, 10/10/2024 - 11:03

122

122

pharmaphorum

OCTOBER 10, 2024

Media personality Nadia Sawalha is heading a fundraising effort to launch an appeal against NICE's recent rejection of a breast cancer therapy Enhertu.

115

115

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Drug Patent Watch

OCTOBER 10, 2024

China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. The country’s vast production capacity, low costs, and strategic location have made it an attractive destination for pharmaceutical companies seeking to source APIs.

Generic Drugs 115

Generic Drugs Marketing Drugs Production 115

Fierce Pharma

OCTOBER 10, 2024

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S. Federal Trade Commission, Lina Khan, Sen. Elizabeth Warren is calling on the antitrust agency to “carefully scrutinize” Novo Holding’s multibillion-dollar bid for CDMO Catalent.

111

111

pharmaphorum

OCTOBER 10, 2024

Starboard Value alleges former Pfizer execs Ian Read and Frank D'Amelio were bullied into lending their support to current management

111

111

Fierce Pharma

OCTOBER 10, 2024

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. Now, with new data indicating the drug could prolong patients’ lives, the company is targeting an even wider label.

FDA Approval 105

FDA Approval Trials Drugs 105

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

pharmaphorum

OCTOBER 10, 2024

EVERSANA partners Oracle on pharmacovigilance platform Phil.

111

111

Outsourcing Pharma

OCTOBER 10, 2024

The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.

Licensing 103

Licensing Licensing Pharma Companies Drugs 103

pharmaphorum

OCTOBER 10, 2024

AI and new technologies: How the pharmaceutical industry is reinventing itself to meet ever more urgent needs Mike.

104

104

Fierce Pharma

OCTOBER 10, 2024

Switzerland’s Competition Commission (COMCO) has dropped its investigation into Novartis’ use of patent actions to quell competition for Cosentyx.

98

98

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials